Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 6/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL22436907 | 1.00 | GRIK1 (0.40) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Aspartic Acid SCHEMBL1680031 | 1.00 | GRIK1 (0.40) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Aspartic Acid SCHEMBL29222914 | 0.95 | GRIK1 (0.37) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Aspartic Acid SCHEMBL5692189 | 0.95 | GRIK1 (0.37) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Aspartic Acid SCHEMBL27659271 | 0.94 | GRIK1 (0.36) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Aspartic Acid SCHEMBL3432993 | 0.94 | GRIK1 (0.36) | GRIK1GRIK2NOS2NOS3NOS1 | |
| D-Glutamate SCHEMBL28246458 | 0.92 | GRIK1 (0.49) | GRIK1GRIK2DPP4BLMKMT2A | |
| Leucine SCHEMBL21122148 | 0.92 | SLC7A5 (0.49) | GRIK1GRIK2DPP4GRIA1GRIA2 | |
| Asparagine SCHEMBL22654328 | 0.89 | NOS2 (0.34) | GRIK1GRIK2NOS2NOS3NOS1 | |
| Asparagine SCHEMBL22654326 | 0.89 | NOS2 (0.34) | GRIK1GRIK2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099436-A1 | NEW DIALYSIS FLUID | GAMBRO LUNDIA AB (SE) | 2023-06-08 | — | — | WO | claimed |
| WO-2023099452-A1 | DIALYSIS FLUID COMPRISING KETONE BODIES FOR THE TREATMENT OF CANCER | GAMBRO LUNDIA AB (SE) | 2023-06-08 | — | — | WO | claimed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | claimed |
| US-5013659-A | Hybrid to resist sulfonylureas | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-07 | — | — | US | claimed |
| US-20240076386-A1 | ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE | PFIZER (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240018261-A1 | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS ALTERED AFFINITIES FOR FcyRActivating and FcyRInhibiting | MACROGENICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11787871-B2 | Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting | MACROGENICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11597770-B2 | Anti-E-selectin antibodies, compositions and methods of use | PFIZER INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4093508-A1 | ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE | Pfizer Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-113528484-B | nCas3 single-stranded endonuclease and application thereof | 湖北大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-113528484-A | nCas3 single-stranded endonuclease and application thereof | 湖北大学 | 2021-10-22 | — | — | CN | disclosed |
| EP-1587540-B1 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME | MACROGENICS INC (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20030158107-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-08-21 | — | — | US | disclosed |
| US-20030134782-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2003-07-17 | — | — | US | disclosed |
| US-6528098-B2 | Viricides | ADVANCED VIRAL RESEARCH CORP. | 2003-03-04 | — | — | US | disclosed |
| US-20020004579-A1 | Preparation of a therapeutic composition | ADVANCED VIRAL RESEARCH CORP. | 2002-01-10 | — | — | US | disclosed |
| EP-0514509-B1 | COMPOSITION AND ITS PREPARATION PROCESS USING ANTIGEN CONJUGATED TO ENZYMATIC ACTIVITY FOR IMMUNOLOGICAL DIAGNOSIS AND CHAGAS' DISEASE IMMUNOLOGICAL DIAGNOSIS KITS, FOR INDIVIDUAL AND EPIDEMIOLOGICAL APPLICATION, BASED ON THAT COMPOSITION | FUNDACAO OSWALDO CRUZ (BR) | 2000-09-20 | — | — | EP | disclosed |
| EP-0314184-B1 | Expression plasmids | BRISTOL MYERS SQUIBB CO (US) | 1995-12-13 | — | — | EP | disclosed |
| CN-1061515-A | PROCESS OF ORANGE PASTE FOODSTUFFS | BEI JUHUA (CN) | 1992-06-03 | — | — | CN | disclosed |
| EP-0314184-A1 | Expression plasmids | Bristol-Myers Squibb Company (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158107-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | GRIK1 3897/4885GRIK2 4093/4885NOS2 3235/4885 |
| US-11597770-B2 | Anti-E-selectin antibodies, compositions and methods of use | SELE, SELP, SELL | GRIK1 4549/4885GRIK2 4593/4885NOS2 3740/4885 |
| US-20020004579-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | GRIK1 3897/4885GRIK2 4093/4885NOS2 3235/4885 |
| US-20030134782-A1 | Preparation of a therapeutic composition | VIP, FCGR3B, FCGRT | GRIK1 3897/4885GRIK2 4093/4885NOS2 3235/4885 |
| US-20240076386-A1 | ANTI-E-SELECTIN ANTIBODIES, COMPOSITIONS AND METHODS OF USE | SELE, SELP, SELL | GRIK1 4549/4885GRIK2 4593/4885NOS2 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.